Pharmafile Logo

biomarkers

- PMLiVE

Prix Galien opens for entries with new award

2018 programme will include new medical technology category

- PMLiVE

GSK’s pipeline cull claims sirukumab, and possibly rare disease unit

Makeover designed to deliver a leaner, fitter company in 2020

Immunotherapies in oncology: the future of cancer treatment lies in combinations and partnerships

Anne Legendre reviews the scientific rationale behind immunotherapy combinations and Frances Hendry examines how partnerships, co-marketing and positioning drugs will play key roles in shaping the competitive landscape in oncology.

Blue Latitude Health

Therapy Watch expands oncology and IBD portfolios

This month Therapy Watch expands its portfolio with the launch of several new trackers across numerous therapy areas including the launch of a new Chronic Myelogenous Leukaemia (CML) study in...

Research Partnership

- PMLiVE

21st Century Cures Act: a commercial perspective on how the new FDA regulation could revolutionise use of RWE and analytics in healthcare

The 21st Century Cures Act has transformed the US drug development landscape. David Cooney explores the implications of the Act for pharmaceutical companies and reveals how it can be leveraged.

Blue Latitude Health

- PMLiVE

Real-world evidence: It’s all in the approach

The merit of real-world evidence in the promotion and use of medicines is increasing and so too are the number of methodologies available

- PMLiVE

Focus on value: A prescription for pharma

The pricing debate demands a common language to be developed

Using service design to improve patients’ quality of life

Customer Experience Consultant Eimear Power talks through the process of developing Orello, a service for metastatic prostate cancer patients and their loved ones, in collaboration with Janssen.

Blue Latitude Health

- PMLiVE

Caring for prostate cancer patients

Although not without its challenges, the appropriate care and support available to patients with prostate cancer is gradually evolving. It’s important not to overlook the all too often ‘unsung heroes’...

Blue Latitude Health

Marketing strategy in complex environments

Age-old treatment protocols are being replaced with new and innovative treatment paradigms that will revolutionise the healthcare industry for years to come. Kulveer Singh and Mark Assenti talk through what...

Blue Latitude Health

- PMLiVE

Novartis’ Zykadia nears first-line lung cancer label

Hopes to boost slow second-line sales to compete directly with Pfizer’s Xalkori and Roche’s Alecensa 

- PMLiVE

Argos hit as kidney cancer immunotherapy fails phase III trial

Study discontinued as data shows renal cell carcinoma vaccine unlikely to meet targets

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links